Overview · Filed: —
ACT_16112/2024
NOVEL ANTITUMORAL USE OF CABAZITAXEL
InfringementMain Infringement ActionMunich LDInfringement Action—
Parties
Claimants
- Sanofi SA (successor of Sanofi Mature IP)(Sanofi Group)
- Sanofi Winthrop Industrie(Sanofi Group)
- Sanofi-Aventis GmbH(Sanofi Group)
- Sanofi Belgium(Sanofi Group)
- Sanofi-Aventis Deutschland GmbH(Sanofi Group)
- Sanofi S.r.l.(Sanofi Group)
- Sanofi B.V.(Sanofi Group)
- Sanofi - Produtos Farmaceuticos Lda(Sanofi Group)
- Sanofi AB(Sanofi Group)
- Sanofi A/S(Sanofi Group)
Reps: Frédéric Chevallier (McDermott Will & Emery)
Respondents
- Accord Healthcare B.V.
- Accord Healthcare, Unipessoal Lda.
- Accord Healthcare S.L.U.
- Accord Healthcare GmbH
- Accord Healthcare Italia Srl
- Accord Healthcare AB
- STADAPHARM GmbH
- STADA Arzneimittel AG
- STADA Nordic ApS
- Reddy Pharma SAS
- betapharm Arzneimittel GmbH
- Dr Reddy's Srl
- Zentiva France
- Zentiva Pharma GmbH
- Zentiva, k.s.
Reps: Jules Fabre (Taylor Wessing); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Anja Lunze (Taylor Wessing)
Judges
- Matthias ZigannPresiding Judge and Judge-Rapporteur
Patents
- EP 2 493 466
CPC codes: A61K38/193, A61K31/573, A61P35/04, A61K31/164, A61K31/56, A61P43/00, A61P13/08, A61P15/00, A61K31/337, A61P35/00, A61K45/06, A61P25/16
Technology area: Pharmaceuticals · Oncology
Sector: Pharmaceutical & Medical
Outcome
Procedural onlyProcedural only (no substantive ruling yet)
Filed: —
First decided: Sep 15, 2025
Language: —